Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Inspira Technologies Oxy BHN ( (IINN) ).
On June 11, 2025, Inspira Technologies announced that its FDA-cleared ART100 system has been successfully integrated into clinical workflows at leading tier-one U.S. hospitals. This integration has generated strong clinical interest and accelerated sales discussions, marking a significant milestone in the company’s commercialization efforts. The ART100’s consistent use has attracted interest from additional U.S. and international healthcare institutions, prompting Inspira to scale up its operational capabilities to support anticipated adoption. This development positions Inspira at the forefront of the rapidly evolving market for life-saving technologies.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company’s U.S. FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. Inspira Technologies is also developing the INSPIRA ART500, a next-generation system, and advancing HYLA™, a proprietary blood sensor platform. The company is positioned as a significant player within the life-support and MedTech landscape.
Average Trading Volume: 500,265
Technical Sentiment Signal: Hold
Current Market Cap: $17.99M
For an in-depth examination of IINN stock, go to TipRanks’ Stock Analysis page.